Ravulizumab Outcomes in Polish Patients with aHUS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, observational cohort collects historical medical data and prospective follow-up to describe how ravulizumab is used in routine practice for aHUS under Poland's National Drug Program. It aims to document longitudinal clinical outcomes and management patterns across multiple Polish sites. The study observes patients of all ages who received ravulizumab through the NDP, with data gathered from past records and ongoing follow-up, without assigning treatment. Participation requires informed consent and excludes individuals enrolled in other aHUS trials or those unable to participate due to language or cognitive barriers. Lead sponsor is AstraZeneca, with sites in Gdansk and Katowice, Poland.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of all ages diagnosed with atypical hemolytic uremic syndrome (aHUS) who received treatment with ravulizumab under the National Drug Program (NDP) in Poland.
* Patients who are willing to participate in the study and have provided informed consent by signing the informed consent form (ICF).

Exclusion Criteria:

* Individuals who intend to participate in a clinical trial for atypical hemolytic uremic syndrome (aHUS) on or after the date of their first ravulizumab infusion through the National Drug Program.
* Patients with cognitive impairments, those who are unwilling to participate, or those facing language barriers that hinder adequate comprehension or cooperation.

Where it's running

• Research Site
  Katowice, Poland Recruiting
• Research Site
  Lodz, Poland Recruiting
• Research Site
  Poznan, Poland Recruiting
• Research Site
  Warsaw, Poland Recruiting
• Research Site
  Wroclaw, Poland Recruiting
• Research Site
  Gdansk, Poland Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center Study Information Center
• Email: information.center@astrazeneca.com
• Phone: +118772409479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ravulizumab for people with clinical aHUS

  This study will test whether ravulizumab raises platelet counts in people diagnosed with clinical atypical hemolytic uremic syndrome (aHUS), including those with certain infections (excluding pneumococcal and STEC), pregnancy/postpartum, recent kidney transplant, malignant hypertension, or autoimmune conditions.

  Recruiting at 3 sites Phase 4 Alexion Pharmaceuticals, Inc. · Bunkyō City and 11 other locations · NCT07308574

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

• Ravulizumab in Chinese adults with NMOSD

  This study tests ravulizumab in Chinese adults with NMOSD who are AQP4 antibody positive to see if it helps reduce relapses and is safe.

  Recruiting Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07557420

• Early ravulizumab for adults with myasthenic crisis in the ICU

  This project will test whether giving ravulizumab early to adults with AChR-positive generalized myasthenia gravis who are in the ICU for a myasthenic crisis helps speed recovery.

  Recruiting at 5 sites Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 7 other locations · NCT07411963

• Oral steroid tapering for adults with generalized myasthenia gravis on ravulizumab.

  This study will try a predefined prednisone taper to see if adults with generalized myasthenia gravis on ravulizumab can safely reduce their daily steroid dose.

  Recruiting Phase 4 Alexion Pharmaceuticals, Inc. · Chicago, Illinois and 11 other locations · NCT07221838

• Ravulizumab for children with IgA nephropathy or IgA vasculitis nephritis

  This trial will test whether intravenous ravulizumab is safe and changes disease markers in children aged 2 to under 18 with biopsy‑proven IgA nephropathy or IgA vasculitis nephritis.

  Recruiting at 13 sites Phase 3 Alexion Pharmaceuticals, Inc. · Palo Alto, California and 14 other locations · NCT07024563

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.